Who Paid My Doc
Michael Glassner
Reproductive Endocrinology Bryn Mawr, PA Medical Doctor
NPI 1740286426 CMS profile 214562
130 S Bryn Mawr Ave, Suite 1000 D Wing, Bryn Mawr, PA 19010
General payments
$2,888
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$13,085
Through program year 2025, Michael Glassner of Bryn Mawr, PA is reported in the CMS Open Payments database as having received $2,888 across 63 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $13,085 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 80th percentile of Reproductive Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $80 | 4 | |
| 2024 | General | $42 | 2 | |
| 2023 | General | $75 | 4 | |
| 2022 | General | $255 | 13 | |
| 2021 | General | $247 | 12 | |
| 2020 | General | $1,901 | 10 | |
| 2019 | General | $288 | 18 |
Beside peers
- Michael Glassner
- Reproductive Endocrinology median
- Middle half of Reproductive Endocrinology
- National median
In program year 2025, general payments to Michael Glassner were reported at $80. Among 986 Reproductive Endocrinology profiles paid that year, the median was $141 and the middle half received between $66 and $285.
Show as a table
| Year | Michael Glassner | Reproductive Endocrinology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $288 | $196 | $77–$425 | $163 |
| 2020 | $1,901 | $81 | $35–$182 | $114 |
| 2021 | $247 | $102 | $43–$247 | $132 |
| 2022 | $255 | $139 | $62–$303 | $149 |
| 2023 | $75 | $141 | $65–$285 | $160 |
| 2024 | $42 | $144 | $65–$302 | $164 |
| 2025 | $80 | $141 | $66–$285 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
63 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Reproductive Endocrinology in Pennsylvania
Anuja Dokras Jagasia
Reproductive Endocrinology · Philadelphia, PA
Kurt Barnhart
Reproductive Endocrinology · Philadelphia, PA
Stephen Somkuti
Reproductive Endocrinology · Abington, PA
Stephanie Estes
Reproductive Endocrinology · Hershey, PA
Richard Legro
Reproductive Endocrinology · Hershey, PA
Julie Rios
Reproductive Endocrinology · Pittsburgh, PA
Related records
Reproductive Endocrinology in Pennsylvania
Practitioners in the same specialty and state, ranked by reported value.
All Reproductive Endocrinology
Everyone recorded under this specialty, nationwide.
Doctors in Pennsylvania
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.